09:34 AM EDT, 08/27/2026 (MT Newswires) -- Argenx (ARGX.BR) completed the acquisition of clinical-stage biopharmaceutical company Forte Biosciences, according to a Thursday release. The immunology company agreed to acquire Forte Biosciences at a total equity valuation of $2.2 billion in late July. It said the acquisition will expand its portfolio, with the addition of Forte Biosciences' lead program, FB102, a first-in-class anti-CD122 antibody with clinical proof-of-concept in vitiligo and celiac disease and potential to address multiple autoimmune diseases.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.